Phase I study to investigate the safety and efficacy of TUR-002 for the treatment of Posttraumatic Stress Disorder (PTSD) at imminent suicide risk (suicidality).

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 12 Jun 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jun 2019 According to a Seelos Therapeutics media release, the company is seeking guidance from the FDA in a scheduled Type C meeting (face to face) over the summer to design and initiate a PoC study in patients with Suicidality-PTSD.
21 May 2019 According to a Seelos Therapeutics media release, the company expects to initiate this study in Q3 2019.
28 Mar 2019 According to a Seelos Therapeutics media release, the company is planning to initiate this study in the summer of 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com